Murohara Toyoaki
Department of Internal Medicine, Division of Cardiology, Nagoya University Graduate School of Medicine.
Nihon Rinsho. 2003 Mar;61(3):485-93.
Therapeutic angiogenesis is an effective means for tissue salvage in patients with critical limb ischemia. Angiogenesis is defined as a formation of new blood vessels by sprouting of preexisting mature endothelial cells(ECs). In contrast, vasculogenesis is referred to as the creation of primordial blood vessels from endothelial progenitor cells (EPCs) or angioblasts. Neovascular formation in adults has been considered to result exclusively from the former process(i.e., angiogenesis). However, we and other researchers recently identified EPCs in human peripheral blood(PB), and circulating EPCs have been shown to accumulate at active angiogenic sites and to participate in neovascularization, a notion consistent with 'postnatal vasculogenesis'. EPCs in adults originate from bone marrow(BM), and we recently have demonstrated that in vivo implantation of autologous BM-MNCs effectively augmented ischemia--induced neovascularization in animal studies as well as human trial(TACT Trial). Here we summarize recent advances in cell transplantation-mediated therapeutic angiogenesis.
治疗性血管生成是挽救严重肢体缺血患者组织的有效手段。血管生成被定义为通过已存在的成熟内皮细胞(ECs)发芽形成新的血管。相比之下,血管发生是指由内皮祖细胞(EPCs)或成血管细胞形成原始血管。成年人的新血管形成一直被认为完全是由前一过程(即血管生成)导致的。然而,我们和其他研究人员最近在人类外周血(PB)中发现了EPCs,并且已证明循环EPCs会在活跃的血管生成部位积聚并参与新血管形成,这一概念与“出生后血管发生”一致。成年人的EPCs起源于骨髓(BM),我们最近在动物研究以及人体试验(TACT试验)中均证明,自体骨髓单个核细胞(BM-MNCs)的体内植入有效增强了缺血诱导的新血管形成。在此,我们总结细胞移植介导的治疗性血管生成的最新进展。